Karen Ferrante

Karen Ferrante

Director/Board Member at COGENT BIOSCIENCES, INC.

Net worth: 58 853 $ as of 31/08/2026

68 year
Health Technology
Consumer Services
Commercial Services

Profile

Dr. Karen J.
Ferrante, MD, is an Independent Director at Cogent Biosciences, Inc. She is on the Board of Directors at Cogent Biosciences, Inc. and New England Women In Science Executives Club.
Dr. Ferrante was previously employed as an Independent Non-Executive Director by HUTCHMED (China) Ltd., an Independent Director by MacroGenics, Inc., an Independent Director by Baxalta, Inc., a Chief Medical Officer, Head-Research & Technology by Tokai Pharmaceuticals, Inc., an Independent Director by Progenics Pharmaceuticals, Inc., a Head-Oncology Therapeutic Area by Takeda Oncology Co., a Head-Oncology Therapeutic Area by Takeda Pharmaceutical Co., Ltd., a Vice President-Oncology Development by Pfizer Inc., an Associate Director by Bristol Myers Squibb Co., and a Vice President-Oncology Department by Pfizer (St. Louis).
She received her undergraduate degree from Providence College and a doctorate degree from Georgetown University.

Known holdings in public companies

CompanyDateNumber of sharesValuationValuation date
19/05/2026 14,750 ( 0.02% ) 58 853 $ 31/08/2026
01/07/2026 0 ( -.--% ) - $ 31/08/2026

Karen Ferrante active positions

CompaniesPositionStart
COGENT BIOSCIENCES, INC. Director/Board Member 01/02/2018
Director/Board Member -

Former positions of Karen Ferrante

CompaniesPositionEnd
MACROGENICS, INC. Director/Board Member 01/09/2026
HUTCHMED (CHINA) LIMITED Director/Board Member 12/05/2023
PROGENICS PHARMACEUTICALS, INC. Director/Board Member 19/06/2020
Chief Tech/Sci/R&D Officer 31/08/2016
BAXALTA INC Director/Board Member 03/06/2016
See the detail of Karen Ferrante's experience

Training of Karen Ferrante

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

Connections

87

1st degree connections

14

1st degree companies

Male

Female

Members of the board

Executives

Linked companies

Private companies14

Health Technology

Health Technology

Health Technology

Health Technology

Health Technology

Health Technology

Health Technology

Health Technology

Health Technology

Consumer Services

Consumer Services

Health Technology

Health Technology

Commercial Services

  1. Stock Market
  2. Insiders
  3. Karen Ferrante